In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma

Background: Glioblastoma represents the most common primary brain tumor in adults. Despite technological advances, patients with this disease typically die within 1–2 years after diagnosis. In the search for novel therapeutics, drug repurposing has emerged as an alternative to traditional drug devel...

Full description

Bibliographic Details
Main Authors: Marc-Eric Halatsch, Annika Dwucet, Carl Julius Schmidt, Julius Mühlnickel, Tim Heiland, Katharina Zeiler, Markus D. Siegelin, Richard Eric Kast, Georg Karpel-Massler
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Pharmaceuticals
Subjects:
CUSP9*
CUSP9v3
glioblastoma
drug repurposing
compassionate use
Online Access:https://www.mdpi.com/1424-8247/14/12/1241

Internet

https://www.mdpi.com/1424-8247/14/12/1241

Similar Items